Biotech Boom Magnifies Biomanufacturing Capacity and Workforce Challenges

Biotech Boom Magnifies Biomanufacturing Capacity and Workforce Challenges
Published on :

The ongoing pandemic response by the biopharma industry has been historic. Biotech companies and contract development and manufacturing organizations, along with the entire supply chain, have worked together to develop several SARS-CoV-2 vaccines, achieved Emergency Use Authorization(EUA) from the FDA, and began delivering desperately needed protection into people’s arms in less than a calendar year.